Edmond de Rothschild

Welcome to our Fund Center

This site provides extensive information about the ranges of Edmond de Rothschild Group funds. In particular, it provides simplified access to key fund-related data (performance, net asset values, features) and their commercial or legal documents.

Please enter your country and indicate which investor category you belong to:
Mobile Logo

EdR Fund Healthcare Thematic equities

Thematic equities
Change in NAV (16/05/2018)
288.88 EUR
Adeline  SALAT-BAROUX–LU1160356694–
Adeline SALAT-BAROUX
Valérie GUELFI–LU1160356694–
Valérie GUELFI
The identity of the managers presented in this document may change during the life of the product.
Risk and reward profile (1)
1234567
Recommended holding period
5 years
288.88 EUR
Change in NAV (16/05/2018)
6
1234567
Risk and reward profile
5 years
Recommended holding period
Change in NAV (16/05/2018)
288.88 EUR
Risk and reward profile
1234567
Recommended holding period
5 years
Adeline SALAT-BAROUX  
Valérie GUELFI  
The identity of the managers presented in this document may change during the life of the product.
Contact

Investment objective

The objective is to grow net assets by investing in companies operating in the healthcare sector, over the recommended investment period.

View more View less

Commentary 30/04/2018

Investor sentiment on the biotech and pharmaceutical sector remains cautious despite continued financial transactions and good quarterly earnings reports. Novartis has continued its development strategy in gene therapy with the acquisition of US-based AveXis for $8.7 billion. The company has a Phase III drug on trial for the treatment of spinal muscular atrophy, a rare disease. Meanwhile, Japan's Takeda has confirmed its interest in the London-listed group Shire (up +8% over the month), hoping to strengthen its position on haemophilia and rare diseases. The fund has benefited from the gains posted by mutual health insurance companies, whose quarterly earnings have come out above expectations. The portfolio's performance was impacted by the bad press given to Acadia over its treatment for Parkinson's disease psychosis. However, the company is standing behind its product risk/benefit profile. The treatment was approved over a year ago by the FDA, which has re-confirmed its product profile. We decided to close our position on the Rite Aid drug distribution network. Albertson has made a cash-and-stock offer for Rite Aid, but we feel there's not enough visibility on this transaction. Instead, we have strengthened our position on CVS, in the same sector.

View more View less

Change in NAV

Chart – Base 100 (16/05/2018)
Avertissement
You are about to download the historical data for a portfolio. Please note that past performance is not an indication of future performance and it may vary over time. They may be affected, for example, by changes in exchange rates

Performance R-EUR Cumulative Annualised
Since 01/01/2018

-0.67 %

2.85 %

-0.67 %

2.85 %

1 Year

-10.51 %

1.54 %

-10.51 %

1.54 %

3 Year

-13.42 %

4.97 %

-4.68 %

1.63 %

5 year

45.56 %

74.44 %

7.79 %

11.76 %

Since inception

188.88 %

240.48 %

12.16 %

14.17 %

Since 01/01/2018 1 Year 3 Year 5 year Since inception
Cumulative

Share class (R-EUR)

Benchmark

-0.67 %

2.85 %

-10.51 %

1.54 %

-13.42 %

4.97 %

45.56 %

74.44 %

188.88 %

240.48 %

Annualised

Share class (R-EUR)

Benchmark

-10.51 %

1.54 %

-4.68 %

1.63 %

7.79 %

11.76 %

12.16 %

14.17 %

*Rolling periods

Annual performance



Statistics

VolatilityTracking ErrorCorrelation coefficientInformation ratioSharpe ratio
Share class R-EURBenchmarkShare class R-EURBenchmarkShare class R-EURBenchmarkShare class R-EURBenchmarkShare class R-EURBenchmark
1 Year*16.02 %14.08 %5.43 %0.94 %-2.33 %-0.14 %
3 Year *14.87 %12.88 %5.53 %0.93 %-1.09 %0.07 %
Max. drawdownAlphaBeta
Share class R-EURBenchmarkShare class R-EURBenchmarkShare class R-EURBenchmark
1 Year*-20.31 %-0.26 %1.07 %
3 Year *-25.81 %-0.50 %1.07 %
Max. monthly gain Since inception12.48 %
Max. monthly loss Since inception-17.75 %
Share class R-EUR
Benchmark
1 Year* 3 Year * 1 Year* 3 Year *
Volatility 16.02 % 14.87 % 14.08 % 12.88 %
Tracking Error 5.43 % 5.53 %
Sharpe ratio -0.14 % 0.07 %
Alpha -0.26 % -0.50 %
Correlation coefficient 0.94 % 0.93 %
Information ratio -2.33 % -1.09 %
Max. monthly loss -17.75 %
Max. monthly gain 12.48 %
Max. drawdown -20.31 % -25.81 %
Beta 1.07 % 1.07 %

Fund information

Inception Date (Fund)
30/04/1985
Inception Date (Part)
17/02/2009
Legal form
SICAV
Benchmark
MSCI AC World Health Care (NR)
Currency (fund)
EUR
Currency (share class)
EUR
Distribution Policy
Accumulation
Valuation frequency
Daily
Minimum initial investment
1 Share
ISIN Code
LU1160356694
AuM (fund)
328 M (EUR)
Regulatory authority
CSSF
EU Regulation
UCITS
Management company
Edmond de Rothschild Asset Management (Luxembourg)
Delegated Management Company
Edmond de Rothschild Asset Management (France)
Incorporation
Luxembourg
Maximum management fee
2,100 %
Current management fee
2.100 %
Subscription and redemption conditions
Daily before 12.30 am C.E.T. on day's net asset value
Subscription fee
3.00 % max
Performance fee
15,000 %

Fund documentation

Select all

(1) The rating grades the funds on a scale from 1 to 7. This rating system is based on the average fluctuations of the net asset value over the past five years. It corresponds to the variation range of the portfolio upwards and downwards. If the net asset value is less than 5 years old, the rating is determined by other regulatory calculation methods. Historical data such as those used to calculate the rating may not be a reliable indication of the future risk profile. The current category is neither a guarantee nor an objective. Category 1 does not signify a risk-free investment.

Top